CN Patent

CN105130992B — 具有激酶抑制活性的含氮杂环化合物、制备方法和用途

Assigned to Taizhou Yiteng Jingang Pharmaceutical Co Ltd · Expires 2018-02-09 · 8y expired

What this patent protects

本发明公开了具有激酶抑制活性的含氮杂环化合物、制备方法和用途，其具有较佳的CDK激酶抑制活性，能对一系列肿瘤细胞增殖产生抑制作用，并且与对照化合物LEE011相比，除了具有较高活性外，较好的克服了LEE011的部分缺陷，具有较好的成药性。

USPTO Abstract

本发明公开了具有激酶抑制活性的含氮杂环化合物、制备方法和用途，其具有较佳的CDK激酶抑制活性，能对一系列肿瘤细胞增殖产生抑制作用，并且与对照化合物LEE011相比，除了具有较高活性外，较好的克服了LEE011的部分缺陷，具有较好的成药性。

Drugs covered by this patent

Patent Metadata

Patent number
CN105130992B
Jurisdiction
CN
Classification
—
Expires
2018-02-09
Drug substance claim
No
Drug product claim
No
Assignee
Taizhou Yiteng Jingang Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.